NuVasive price target raised to $22 from $19 at RW Baird Baird raised its price target on NuVasive following solid Q4 results. The firm cited reasons to expect higher revenue growth on better than expected leverage opportunities. Baird likes the risk/reward and maintains its Outperform rating.
NuVasive CEO news an incremental positive, says Piper Jaffray Piper Jaffray views NuVasive's naming Greg Lucier as its permanent CEO as an incremental positive despite the executive's lack direct experience in the spine industry. Piper notes its channel checks indicate no meaningful sales force disruption from the CEO transition. It reiterates an Overweight rating on NuVasive with a $56 price target.